UCB Gets US FDA Approval for Psoriasis Drug
By Helena Smolak
UCB received approval from the U.S. Food and Drug Administration for a drug to treat severe plaque psoriasis for which the company expects global peak annual sales of at least 4 billion euros ($4.23 billion).
The Belgian biopharmaceutical firm said Wednesday that its bimekizumab drug, which will be commercialized as Bimzelx, was approved by the FDA as a treatment for the skin disease psoriasis in adults.
"With bimekizumab now approved for psoriasis, we will move forward rapidly to submit applications for additional indications in the U.S.", it said.
The FDA approval was backed by data from three Phase 3 studies, the company said.
UCB on Tuesday said the FDA approved its Zilbrysq for the treatment of adults with myasthenia, an autoimmune disorder.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
October 18, 2023 11:21 ET (15:21 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
Arm Earnings: Shares Fall as 2025 Guidance Disappoints Investors